Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Ian

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
Neuro-Oncology|December 21, 2016
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813Susan Chang, Peixin Zhang, J Gregory Cairncross, et al.
Neuro-Oncology|March 22, 2008
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasKathleen R Lamborn, W K Alfred Yung, Susan M Chang, et al.
Cancer|March 11, 2020
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcomaEudocia Q Lee, Peixin Zhang, Patrick Y Wen, et al.
Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Brain Pathology (Zurich, Switzerland)|March 5, 2013
Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous systemAditya Raghunathan, Khalida Wani, Terri S Armstrong, et al.
Neuro-Oncology|March 19, 2009
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Neuro-Oncology Advances|October 27, 2022
Germline polymorphisms in <i>MGMT</i> associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825Michael E Scheurer, Renke Zhou, Mark R Gilbert, et al.
Neuro-Oncology|November 16, 2024
Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825Joshua D Strauss, Mark R Gilbert, Minesh Mehta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2012
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03Eudocia Q Lee, Vinay K Puduvalli, Joel M Reid, et al.
JAMA Oncology|June 30, 2018
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 TrialErica H Bell, Peixin Zhang, Barbara J Fisher, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
Neuro-Oncology|December 21, 2016
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813Susan Chang, Peixin Zhang, J Gregory Cairncross, et al.
Neuro-Oncology|March 22, 2008
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomasKathleen R Lamborn, W K Alfred Yung, Susan M Chang, et al.
Cancer|March 11, 2020
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcomaEudocia Q Lee, Peixin Zhang, Patrick Y Wen, et al.
Neuro-Oncology|January 29, 2014
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Patrick Y Wen, Susan M Chang, Kathleen R Lamborn, et al.
Brain Pathology (Zurich, Switzerland)|March 5, 2013
Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous systemAditya Raghunathan, Khalida Wani, Terri S Armstrong, et al.
Neuro-Oncology|March 19, 2009
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Neuro-Oncology Advances|October 27, 2022
Germline polymorphisms in <i>MGMT</i> associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825Michael E Scheurer, Renke Zhou, Mark R Gilbert, et al.
Neuro-Oncology|November 16, 2024
Clinical and genetic markers of vascular toxicity in glioblastoma patients: Insights from NRG Oncology RTOG-0825Joshua D Strauss, Mark R Gilbert, Minesh Mehta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2012
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03Eudocia Q Lee, Vinay K Puduvalli, Joel M Reid, et al.
JAMA Oncology|June 30, 2018
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 TrialErica H Bell, Peixin Zhang, Barbara J Fisher, et al.
Pageof 12